News | Page 2 of 10 | 53Biologics

October 28, 2025 Patricia De La Madrid Comments: 0

Project Management in Biologics Development: Keys to Successful CDMO Collaboration

Biologics development is complex. Each project involves multiple stakeholders, tight timelines and strict regulatory standards. For companies working with a Contract Development and Manufacturing Organization (CDMO), strong project management is the key to transform complexity into clarity. Without it, delays, cost overruns and miscommunication can easily derail progress. 1. Why Project Management Matters A biologics program spans many stages: cell line development, process optimization, scale-u...

October 17, 2025 Patricia De La Madrid Comments: 0

53Biologics featured in APTE Technonews for its innovation in RNA enzyme production

53Biologics has been featured in the latest edition of APTE Technonews (Issue 91), the magazine of the Spanish Association of Science and Technology Parks. The article highlights our contribution to innovation in RNA enzyme manufacturing. This is a cornerstone technology enabling mRNA vaccines, gene therapy and next-generation RNA-based treatments. The challenge of RNA enzyme manufacturing RNA-based therapeutics rely on high-performance enzymes such as RNA polymerase, essential for accurate RNA...

October 7, 2025 Patricia De La Madrid Comments: 0

Overcoming Bottlenecks in Downstream Processing

In biologics manufacturing, upstream production often captures much of the spotlight. Fermentation, cell culture and expression systems are frequently discussed as the heart of drug development. Yet, for many companies, the true bottleneck lies downstream, in purification. Chromatography and filtration steps that work well at bench scale can become major hurdles when scaled to industrial volumes. At 53Biologics, we understand that downstream processing is where efficiency, cost control and produ...

September 25, 2025 Patricia De La Madrid Comments: 0

Critical Quality Attributes (CQAs) in Biologics Manufacturing: Why They Matter

When it comes to biologics, quality is not just important, it is everything. Unlike small molecules, biologics are produced by living systems, which makes them more complex, more variable and more sensitive to manufacturing conditions. To ensure safety and efficacy, regulators require companies to define and monitor Critical Quality Attributes (CQAs) throughout development and production. At 53Biologics, we see CQAs as the blueprint of product quality. By identifying them early and controlling t...

September 12, 2025 Patricia De La Madrid Comments: 0

Ensuring Consistency in Cell Banking: Best Practices for Biologics Manufacturing

At 53Biologics, we believe that cell banking is the cornerstone of biologics manufacturing. It is the foundation on which large-scale production is built, ensuring that every batch is consistent, safe and effective. Behind every successful biologic drug lies a reliable cell bank. Whether producing therapeutic proteins, monoclonal antibodies, or enzymes, biologics manufacturing depends on stable, well-characterized cell lines. Without them, reproducibility and regulatory compliance would be impos...

September 3, 2025 Patricia De La Madrid Comments: 0

From Plasmid DNA to Viral Vectors: The Backbone of Gene Therapy

Plasmid DNA (pDNA) has become the essential starting material in modern gene therapy. Without it, producing reliable viral vectors would not be possible. As the field of gene therapy expands, ensuring that pDNA is manufactured at the right scale, purity, and regulatory standard is becoming one of the defining challenges for biotech companies. At 53Biologics, we see plasmid DNA as much more than a raw material: it is the backbone of the entire gene therapy ecosystem. Understanding its role, the c...

August 18, 2025 Patricia De La Madrid Comments: 0

Is the Biopharma World Ready for Artificial Intelligence?

Artificial intelligence (AI) has already become part of everyday life, and it is beginning to reshape the biopharma industry. Its potential is undeniable: accelerating drug discovery, optimizing manufacturing, and bringing therapies to patients faster. Yet readiness remains low—only 14% of large biopharma companies and 3% of smaller ones are prepared to adopt AI, according to Benchling. Artificial Intelligence Roadblocks in Pharma For big pharma, the challenge is complexity. Years of using mul...

August 1, 2025 Patricia De La Madrid Comments: 0

Why Some Biologics Manufacturing Processes Fail to Scale: Challenges and Solutions from 53Biologics

Scaling up biologics manufacturing from lab-scale to GMP production is a critical step that often presents unexpected challenges. While early-stage processes may work efficiently on a small scale, not all bioprocesses translate smoothly to larger volumes or industrial environments. Understanding these obstacles is key for successful technology transfer and commercialization. Common Challenges in Scaling Biologics Manufacturing 1. Biological Complexity and Variability Biologics such as recombinan...

July 22, 2025 Patricia De La Madrid Comments: 0

How GMP Biologics Manufacturing Is Evolving: What 53Biologics Is Doing Differently in 2025

The biopharmaceutical industry is rapidly advancing, with GMP biologics manufacturing at the heart of this transformation. With rising demand for scalable biologics, CDMOs like 53Biologics must continuously adapt to client and regulatory expectations. In 2025, 53Biologics stands out by pairing robust GMP manufacturing with agile, tailored solutions for microbial and mammalian biologics production. Meeting the Rising Demand for Microbial Biologics Microbial expression systems such as E. coli and...

July 8, 2025 Patricia De La Madrid Comments: 0

Choosing the Right Cell Line Strategy: Licensed vs. Unlicensed Cell Lines in Biologics Development

Selecting the optimal cell line is a critical early decision in the development of any biologic drug. It can impact everything from expression yields and product quality to regulatory timelines and commercial strategy. One key consideration for many developers is whether to use a licensed or unlicensed cell line, and the right answer depends on the specific goals, timeline, and product profile. At 53Biologics, we do not offer proprietary strains or cell lines. Instead, we prioritize flexibility....